Data Year:
Select Other Years

For its 2025 fiscal year, CG ONCOLOGY INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Arthur Kuan
Chief Executive Officer
Total Compensation $11,928,401 View details Pay Rank By Title In Biotechnology industry #81 View more
Vijay Kasturi
Chief Medical Officer
Total Compensation $3,599,946 View details Pay Rank By Title In Biotechnology industry #59 View more
Ambaw Bellete
President and Chief Operating Officer
Total Compensation $4,815,392 View details Pay Rank By Title In Biotechnology industry #24 View more
Corleen Roche
Prior Chief Financial Officer
Total Compensation $2,322,299 View details Pay Rank By Title In Biotechnology industry #195 View more
Robert Lapetina
Prior Interim Principal Financial and Accounting Officer
Total Compensation $645,297 View details Pay Rank By Title In Biotechnology industry #485 View more
Joshua F. Patterson
General Counsel, Chief Compliance Officer, and Secretary
Total Compensation $2,364,380 View details Pay Rank By Title In Biotechnology industry #40 View more
Jim DeTore
Chief Financial Officer
Total Compensation $96,000 View details Pay Rank By Title In Biotechnology industry #666 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at CG ONCOLOGY INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. CG ONCOLOGY INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. CG ONCOLOGY INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Arthur Kuan
Chief Executive Officer
Total Cash $1,104,000 Equity $10,802,399 Other $22,002 $11,928,401
Vijay Kasturi
Chief Medical Officer
Total Cash $729,251 Equity $2,839,963 Other $30,732 $3,599,946
Ambaw Bellete
President and Chief Operating Officer
Total Cash $806,912 Equity $3,967,601 Other $40,879 $4,815,392
Corleen Roche
Prior Chief Financial Officer
Total Cash $288,890 Equity $2,004,682 Other $28,727 $2,322,299
Robert Lapetina
Prior Interim Principal Financial and Accounting Officer
Total Cash $312,474 Equity $300,702 Other $32,121 $645,297
Joshua F. Patterson
General Counsel, Chief Compliance Officer, and Secretary
Total Cash $669,208 Equity $1,670,561 Other $24,611 $2,364,380
Jim DeTore
Chief Financial Officer
Total Cash $96,000 Equity $0 Other $0 $96,000
For its 2025 fiscal year, CG ONCOLOGY INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Arthur Kuan CEO Pay $11,928,401 Median Employee Pay $301,336 CEO Pay Ratio 40:1
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.